Investment opportunities

69 days remaining
Target
€1.200.000
Invested
46.2%
63,7% Committed

Hemerion

flag

Hemerion develops unique light-based therapies to extend and save lives of cancer patients.

64 days remaining
Target
€500.000
Invested
73.4%
74,5% Committed

MSInsight

flag

MSInsight utilizes cutting-edge DNA sequencing to deliver highly accurate cancer tests, ensuring precise diagnoses and tailored treatments.

64 days remaining
Target
€1.000.000
Invested
42.7%
43,3% Committed

Biointaxis

Biointaxis develops and brings to market gene therapies for neurological diseases.

64 days remaining
Target
€300.000
Invested
65.0%
72,5% Committed

Dipneo

The first CPR ventilation device suitable for all types of users in out-of-hospital cardiac arrest situations.

8 days remaining
Target
€500.000
Invested
100.1%
105,7% Committed

Improfit.AI

B2B SaaS solutions providing AI-powered computer vision tools for digitizing rehabilitation.

81 days remaining
Target
€2.000.000
Invested
54.9%
64,4% Committed

Pharmamel

Development of new melatonin-based drugs for sepsis, inflammatory, and viral diseases.

15 days remaining
Target
€575.000
Invested
109.0%
114,9% Committed

Spinally

Introducing FuturaLead: The miniaturized spinal cord implant for a pain-free life.

49 days remaining
Target
€500.000
Invested
96.9%
99,8% Committed

Open Stent Solution

flag

Your support extends beyond funding a device; it catalyzes a transformative shift in healthcare.

Successfully closed!
Target
€600.000
Invested
133.1%

Flomics

Flomics is developing a liquid biopsy test that can detect cancer even before the first symptoms appear, everything out of a blood sample.

Successfully closed!
Target
€1.000.000
Invested
106.3%

Oncoheroes Biosciences Inc.

The world's first biotech company dedicated exclusively to developing drugs for pediatric cancer.

Successfully closed!
Target
€400.000
Invested
105.8%

MOWOOT 2024

Innovative, non-invasive, non-drug solution for bowel dysfunction (BD)

Successfully closed!
Target
€800.000
Invested
140.6%

NUUBO 2024